The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors

Clinica Chimica Acta

Volumn 261, Issue 1, 1997, Pages 43-56

  Sidelmann, Johannes ^a   Jespersen, Jørgen ^a   Kluft, Cornelis ^a,b   Gram, Jørgen ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b TNO   (Netherlands)

Author keywords

Chemical anti inhibitors; Fibrinolysis; Inhibitors; Serine proteases

Indexed keywords

ANTIPLASMIN; DODECYL SULFATE SODIUM; ENZYME INHIBITOR; FLUFENAMIC ACID; METHYLAMINE; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TOSYLCHLORAMIDE SODIUM;

ANALYTIC METHOD; ARTICLE; CONCENTRATION RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INACTIVATION; ENZYME INHIBITION; FIBRINOLYSIS; HUMAN; PLASMA; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL;

CHLORAMINES; ENZYME ACTIVATION; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; FLUFENAMIC ACID; HUMANS; METHYLAMINES; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; SERINE PROTEINASE INHIBITORS; SODIUM DODECYL SULFATE; TISSUE PLASMINOGEN ACTIVATOR; TOSYL COMPOUNDS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031002934     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(97)06517-0     Document Type: Article

References (24)

1. Müllertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976;159:545-553.
2. Kruithof EKO, Tran-Thang C, Bachmann F. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemost 1986;55:65-69.
3. Blix S. Studies on the fibrinolytic system in the euglobulin fraction of human plasma. Scand J Clin Lab Invest 1961; 13 (Suppl. 58): 1-19.
4. de Maat MPM, Kluft C, Boer KD, Knot EAR, Jie AFH. Acid treatment of plasma for the inactivation of plasminogen activator inhibitor-1 (PAI-1). Thromb Res 1988;52:425-430.
5. Rånby M, Sundell B, Nilsson TK. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal t-PA activity. Thromb Haemost 1989;62:917-922.
6. Stief TW, Lenz P, Becker U, Heimburger N. Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants: A novel principle. Thromb Res 1988;50:559-573.
7. Stief TW, Aab A, Heimburger N. Oxidative inactivation of purified human alpha-2-antiplasmin. antithrombin III, and C1-inhibitor. Thromb Res 1988;49:581-589.
8. Kluft C. Elimination of inhibition in euglobulin fibrinolysis by use of flufenamate: Involvement of C1-inactivator. Haemostasis 1977;6:351-369.
9. 2-antiplasmin and purified human C1 inhibitor by synthetic fibrinolytic agents. Blood 1981;57:1015-1024.
10. Gaussem P, Grailhe P, Anglés-Cano E. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor. J Biol Chem 1993;268:12150-12155.
11. Urano T, Strandberg L, Johansson LBÅ. A substrate form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992;209:985-992.
12. Yan D, Urano T, Takada Y, Takada A. Dissociation of α2-plasmin-inhibitor-plasmin complex and regeneration of plasmin activity by SDS treatment. Thromb Res 1993;69:491-499.
13. Larsson LH, Olson ST, Björk I. Kinetics of conformational changes and inactivation of human alpha2-macroglobulin on reaction with methylamine. Biochemistry 1985;24:1585-1593.
14. 2-macroglobulin. Ann NY Acad Sci 1983;421:160-166.
15. 2-antiplasmin, histidine-rich glycoprotein, and protein C in patients with acute myocardial infarction and deep vein thrombosis. Thromb Haemost 1985;54:503-505.
16. Lind SE, McDonagh R, Smith CJ. Oxidative inactivation of plasmin and other serine proteases by copper and ascorbate. Blood 1993;82:1522-1531.
17. von Kaulla KN. On the in vitro mechanism of synthetic fibrinolytic agents. In: Schor JM, editors. Chemical control of fibrinolysis-thrombolysis. Theory and clinical applications. New York: Wiley-Interscience, 1970:1-41.
18. Brakman P. Fibrinolysis. A standardized fibrin plate method and a fibrinolytic assay of plasminogen. Thesis. Amsterdam: Scheltema and Holkema, 1967.
19. Sidelmann J, Jespersen J, Gram J. Plasminogen activator activity and plasma-coagulum lysis measured by use of optimized fibrin gel structure preformed in microtiter plates. Clin Chem 1995:41:979-985.
20. Shechter Y, Burstein Y, Patchornik A. Selective oxidation of methionine residues in proteins. Biochemistry 1975;14:4497-4503.
21. Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A. PA[-] plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991;66:474-478.
22. Kluft C. Occurence of C1 inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity. Haemostasis 1976;5:136-146.
23. Thorsen S, Müllertz S, Suenson E, Kok P. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Biochem J 1984;223:179-187.
24. Chevallet-Prandini MH, Chapel A, Suscillon M. The fibrinolytic action of flufenamate and its influence on plasminogen binding to fibrin. Thromb Res 1985;38:481-489.